SCHEMBL4123392

SCHEMBL4123392

CCOC(=O)C(C(=O)OCC)C(=O)C(C)(CC(C)C)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
PIN1 Q13526 2/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 2/20 0.40
MMP8 P22894 3/20 0.39
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRIN2D O15399 2/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2A Q12879 2/20 0.38
GRIN2B Q13224 2/20 0.38
GRIN2C Q14957 2/20 0.38
OPRM1 P35372 2/20 0.38
TSHR P16473 2/20 0.38
CACNA1F O60840 1/20 0.38
ABCB1 P08183 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999030 0.86 PIN1 (0.40) MAPTPIN1MEN1NPC1KMT2A
SCHEMBL4000607 0.86 PIN1 (0.40) MAPTPIN1MEN1NPC1KMT2A
SCHEMBL3999925 0.86 PIN1 (0.40) MAPTPIN1MEN1NPC1KMT2A
SCHEMBL11415156 0.85 MMP8 (0.46) MAPTPIN1MEN1NPC1KMT2A
SCHEMBL4000449 0.84 PIN1 (0.43) PIN1MEN1NPC1KMT2APOLB
SCHEMBL4127273 0.82 PIN1 (0.42) PIN1MEN1NPC1KMT2APOLB
SCHEMBL4007259 0.82 PIN1 (0.42) PIN1MEN1NPC1KMT2APOLB
SCHEMBL1627161 0.81 PIN1 (0.46) MAPTPIN1MEN1NPC1KMT2A
SCHEMBL4123395 0.81 MAPT (0.42) MAPTMEN1KMT2ASMN1; SMN2GRIN2D
SCHEMBL4007055 0.81 KIF11 (0.42) PIN1MEN1NPC1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032177-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed
WO-2009032177-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II POLR2E, POLR2H, POLR2A MAPT 4141/4885PIN1 1263/4885MEN1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.